Copyright
©The Author(s) 2019.
World J Gastroenterol. Apr 14, 2019; 25(14): 1684-1696
Published online Apr 14, 2019. doi: 10.3748/wjg.v25.i14.1684
Published online Apr 14, 2019. doi: 10.3748/wjg.v25.i14.1684
Figure 2 Immunohistochemical staining for programmed death 1, CD8, and FOXP3 in human gastric neuroendocrine carcinomas.
A: The programmed death 1 positive infiltrating lymphocytes; B: CD8 positive lymphocytes; C: FOXP3 positive Treg cells.
- Citation: Yang MW, Fu XL, Jiang YS, Chen XJ, Tao LY, Yang JY, Huo YM, Liu W, Zhang JF, Liu PF, Liu Q, Hua R, Zhang ZG, Sun YW, Liu DJ. Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas. World J Gastroenterol 2019; 25(14): 1684-1696
- URL: https://www.wjgnet.com/1007-9327/full/v25/i14/1684.htm
- DOI: https://dx.doi.org/10.3748/wjg.v25.i14.1684